WO2004101483A1 - 新規3置換ベンゼン誘導体、その製造方法、およびそれを含む医薬組成物 - Google Patents
新規3置換ベンゼン誘導体、その製造方法、およびそれを含む医薬組成物 Download PDFInfo
- Publication number
- WO2004101483A1 WO2004101483A1 PCT/JP2004/006546 JP2004006546W WO2004101483A1 WO 2004101483 A1 WO2004101483 A1 WO 2004101483A1 JP 2004006546 W JP2004006546 W JP 2004006546W WO 2004101483 A1 WO2004101483 A1 WO 2004101483A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- hydrogen atom
- alkyl group
- hydroxymethyl
- pharmaceutically acceptable
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 9
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title claims description 28
- 239000000203 mixture Substances 0.000 title abstract description 21
- 229940079593 drug Drugs 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 126
- 208000028389 Nerve injury Diseases 0.000 claims abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 21
- 230000008764 nerve damage Effects 0.000 claims abstract description 21
- 208000008589 Obesity Diseases 0.000 claims abstract description 19
- 235000020824 obesity Nutrition 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 111
- 125000003118 aryl group Chemical group 0.000 claims description 82
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 81
- 150000003839 salts Chemical class 0.000 claims description 52
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 36
- 125000003282 alkyl amino group Chemical group 0.000 claims description 26
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 22
- 125000003342 alkenyl group Chemical group 0.000 claims description 22
- 150000004677 hydrates Chemical class 0.000 claims description 22
- 230000026731 phosphorylation Effects 0.000 claims description 22
- 238000006366 phosphorylation reaction Methods 0.000 claims description 22
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 20
- 230000003449 preventive effect Effects 0.000 claims description 19
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000003277 amino group Chemical group 0.000 claims description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
- 239000003623 enhancer Substances 0.000 claims description 14
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 206010029333 Neurosis Diseases 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 208000015238 neurotic disease Diseases 0.000 claims description 13
- 229940126585 therapeutic drug Drugs 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 230000000069 prophylactic effect Effects 0.000 claims description 9
- DCLJORLKXICIIJ-UHFFFAOYSA-N 3-hexyl-2-(hydroxymethyl)phenol Chemical compound CCCCCCC1=CC=CC(O)=C1CO DCLJORLKXICIIJ-UHFFFAOYSA-N 0.000 claims description 8
- XLXZRDMCQYZOHP-UHFFFAOYSA-N 2-(hydroxymethyl)-3-(2-phenylethenyl)phenol Chemical compound OCC1=C(O)C=CC=C1C=CC1=CC=CC=C1 XLXZRDMCQYZOHP-UHFFFAOYSA-N 0.000 claims description 7
- 238000005984 hydrogenation reaction Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 201000001119 neuropathy Diseases 0.000 claims description 7
- 230000007823 neuropathy Effects 0.000 claims description 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 7
- 125000006039 1-hexenyl group Chemical group 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- XHLFAURCAXYYLH-UHFFFAOYSA-N 2-(hydroxymethyl)-3-prop-1-enylphenol Chemical compound CC=CC1=CC=CC(O)=C1CO XHLFAURCAXYYLH-UHFFFAOYSA-N 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- BZOHHLMTCXVRJE-UHFFFAOYSA-N 2-(hydroxymethyl)-1,3-dihydroinden-2-ol Chemical compound C1=CC=C2CC(CO)(O)CC2=C1 BZOHHLMTCXVRJE-UHFFFAOYSA-N 0.000 claims description 4
- 229940043274 prophylactic drug Drugs 0.000 claims description 4
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 4
- AQHANRVDTSURKY-UHFFFAOYSA-N 2-but-2-en-2-ylphenol Chemical compound CC=C(C)C1=CC=CC=C1O AQHANRVDTSURKY-UHFFFAOYSA-N 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000732 arylene group Chemical group 0.000 claims 4
- 125000006019 1-methyl-1-propenyl group Chemical group 0.000 claims 3
- OJZOQUSWGHERID-UHFFFAOYSA-N 3-ethenyl-2-(hydroxymethyl)phenol Chemical compound OCC1=C(O)C=CC=C1C=C OJZOQUSWGHERID-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 5
- 208000018737 Parkinson disease Diseases 0.000 abstract description 5
- -1 3-substituted benzene Chemical class 0.000 description 33
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 102000004877 Insulin Human genes 0.000 description 16
- 108090001061 Insulin Proteins 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 229940125396 insulin Drugs 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 230000009471 action Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 108010025020 Nerve Growth Factor Proteins 0.000 description 11
- 102000015336 Nerve Growth Factor Human genes 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000005416 organic matter Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- NWHKKDLPTKZXQK-UHFFFAOYSA-N 1,2-dioxin-4-one Chemical compound O=C1COOC=C1 NWHKKDLPTKZXQK-UHFFFAOYSA-N 0.000 description 4
- AKEUNCKRJATALU-UHFFFAOYSA-N 2,6-dihydroxybenzoic acid Chemical compound OC(=O)C1=C(O)C=CC=C1O AKEUNCKRJATALU-UHFFFAOYSA-N 0.000 description 4
- NELNKGSSZADTED-UHFFFAOYSA-N 5-hexyl-2,2-dimethyl-1,3-benzodioxin-4-one Chemical compound O1C(C)(C)OC(=O)C2=C1C=CC=C2CCCCCC NELNKGSSZADTED-UHFFFAOYSA-N 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 150000001555 benzenes Chemical class 0.000 description 4
- 210000005056 cell body Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 3
- PVOAPVDFUFGKNM-UHFFFAOYSA-N 1,3-benzodioxin-4-one Chemical compound C1=CC=C2C(=O)OCOC2=C1 PVOAPVDFUFGKNM-UHFFFAOYSA-N 0.000 description 3
- URHWMZVMAAUENN-UHFFFAOYSA-N 1,3-dioxin-4-one Chemical compound O=C1OCOC=C1 URHWMZVMAAUENN-UHFFFAOYSA-N 0.000 description 3
- XHLFAURCAXYYLH-DUXPYHPUSA-N 2-(hydroxymethyl)-3-[(e)-prop-1-enyl]phenol Chemical compound C\C=C\C1=CC=CC(O)=C1CO XHLFAURCAXYYLH-DUXPYHPUSA-N 0.000 description 3
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 3
- XQUVTYAQELBOQV-UHFFFAOYSA-N 3-hex-1-enyl-2-(hydroxymethyl)phenol Chemical compound CCCCC=CC1=CC=CC(O)=C1CO XQUVTYAQELBOQV-UHFFFAOYSA-N 0.000 description 3
- 125000005917 3-methylpentyl group Chemical group 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000003746 Insulin Receptor Human genes 0.000 description 3
- 108010001127 Insulin Receptor Proteins 0.000 description 3
- 229910010082 LiAlH Inorganic materials 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 125000006038 hexenyl group Chemical group 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 2
- UIAFKZKHHVMJGS-UHFFFAOYSA-N 2,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1O UIAFKZKHHVMJGS-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- XBHJTSIYYWRJFQ-MDZDMXLPSA-N 3-[(e)-2-phenylethenyl]phenol Chemical compound OC1=CC=CC(\C=C\C=2C=CC=CC=2)=C1 XBHJTSIYYWRJFQ-MDZDMXLPSA-N 0.000 description 2
- GUSKFNLJEGYBQO-UHFFFAOYSA-N 3-but-2-en-2-yl-2-(hydroxymethyl)phenol Chemical compound CC=C(C)C1=CC=CC(O)=C1CO GUSKFNLJEGYBQO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000028591 pheochromocytoma Diseases 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- MOSYEQKMVNBDAL-XQRVVYSFSA-N 2,2-dimethyl-5-[(Z)-prop-1-enyl]-1,3-benzodioxin-4-one Chemical compound C\C=C/c1cccc2OC(C)(C)OC(=O)c12 MOSYEQKMVNBDAL-XQRVVYSFSA-N 0.000 description 1
- 229940082044 2,3-dihydroxybenzoic acid Drugs 0.000 description 1
- XLXZRDMCQYZOHP-MDZDMXLPSA-N 2-(hydroxymethyl)-3-[(e)-2-phenylethenyl]phenol Chemical compound OCC1=C(O)C=CC=C1\C=C\C1=CC=CC=C1 XLXZRDMCQYZOHP-MDZDMXLPSA-N 0.000 description 1
- FDRYLQLJDODPHA-UHFFFAOYSA-N 2-(hydroxymethylamino)phenol Chemical compound OCNC1=CC=CC=C1O FDRYLQLJDODPHA-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- KNKURLNQYHFGOQ-DUXPYHPUSA-N 3-[(e)-prop-1-enyl]phenol Chemical compound C\C=C\C1=CC=CC(O)=C1 KNKURLNQYHFGOQ-DUXPYHPUSA-N 0.000 description 1
- YNGIFMKMDRDNBQ-UHFFFAOYSA-N 3-ethenylphenol Chemical compound OC1=CC=CC(C=C)=C1 YNGIFMKMDRDNBQ-UHFFFAOYSA-N 0.000 description 1
- GCOZFWFNEBPOJF-UHFFFAOYSA-N 5-hydroxy-2,2-dimethyl-1,3-benzodioxin-4-one Chemical compound C1=CC=C2OC(C)(C)OC(=O)C2=C1O GCOZFWFNEBPOJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- PWATWSYOIIXYMA-UHFFFAOYSA-N Pentylbenzene Chemical compound CCCCCC1=CC=CC=C1 PWATWSYOIIXYMA-UHFFFAOYSA-N 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- KDFQYGBJUYYWDJ-UHFFFAOYSA-N azane;sodium Chemical compound N.[Na] KDFQYGBJUYYWDJ-UHFFFAOYSA-N 0.000 description 1
- 229940114055 beta-resorcylic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000002638 heterogeneous catalyst Substances 0.000 description 1
- QJDCJRCNGGXETD-UHFFFAOYSA-N hex-1-enoxyboronic acid Chemical compound CCCCC=COB(O)O QJDCJRCNGGXETD-UHFFFAOYSA-N 0.000 description 1
- 239000002815 homogeneous catalyst Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002815 nickel Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006464 oxidative addition reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- AHEHMEDQTGXXRH-UHFFFAOYSA-N prop-1-enoxyboronic acid Chemical compound CC=COB(O)O AHEHMEDQTGXXRH-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/18—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring
- C07C39/19—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
Definitions
- the present invention relates to a novel trisubstituted benzene derivative, a method for producing the same, and a pharmaceutical composition containing the trisubstituted benzene derivative.
- diabetes is a disease that produces characteristic symptoms such as polyuria and polysaccharide as a result of insufficient insulin secretion in the islets of Langerhans or tissue resistance of insulin action at target tissues.
- characteristic symptoms such as polyuria and polysaccharide as a result of insufficient insulin secretion in the islets of Langerhans or tissue resistance of insulin action at target tissues.
- One of the factors that attenuates the insulin action is considered to be a decrease in the activation of the insulin receptor in target cells.
- One possible cause of the decrease in insulin receptor activation is the decrease in the activity of the tyrosine kinase (an enzyme that phosphorylates tyrosine residues in proteins) possessed by the insulin receptor.
- Factors that attenuate tyrosine kinase activity include, for example, PTPlB (protein tyrosine phosphatase IB), one of tyrosine phosphatases (protein phosphatases specific to phosphorylated tyrosine residues in proteins), antagonize insulin action.
- PTPlB protein tyrosine phosphatase IB
- tyrosine phosphatases protein phosphatases specific to phosphorylated tyrosine residues in proteins
- LAR lukocyte common antigen-related phosphatase
- the protein nerve growth factor NGF which is thought to be useful as a therapeutic and / or prophylactic agent for neurodegenerative diseases, undergoes neuronal dendrites via its receptor Trk family, and the like. It forms a network circuit and exerts a neuroprotective effect.
- the Trk family is a receptor that has tyrosine kinase activity, and compounds that enhance the action of this nerve growth factor NGF are useful for preventing nerve damage, Alzheimer's disease, Parkinson's disease, etc. It may be a therapeutic and / or prophylactic agent for diseases such as neurosis (Neuroscience Lett., 66, 175 (1986), Brain Res. 661, 137 (1994)).
- the present invention provides a novel compound for overcoming diseases including neuropathy such as diabetes or obesity, or nerve damage, Alzheimer's disease, and Parkinson's disease, and a drug containing the same. is there. More specifically, the present invention provides a compound capable of enhancing the action of insulin or NGF, and a drug containing the compound.
- the present inventor has proposed and synthesized a compound that effectively enhances the action of insulin and NGF, and as a result of repeated studies, has led to the development of the compound according to the present invention.
- the present inventors have conducted intensive studies to solve the above problems, and as a result, have found a novel 3-substituted benzene, and a composition containing the same has been used for diabetes or obesity, nerve damage, Alzheimer's disease, Parkinson's disease, etc. Have been found to be drugs that can overcome diseases including neurosis.
- the present invention is as follows.
- -R 6 represents an alkyl group, an aryl group, or an alkylamino group
- R 2 represents a formyl group
- a carboxy group, -CH _0 (C 0)
- R 7 represents an alkyl group, an aryl group, or an alkylamino group
- R 8 represents a hydrogen atom, an alkyl group, or an alkenyl group
- R 9 represents a hydrogen atom or an alkyl group
- -CH CH-R 1Q
- R 1Q represents an alkyl group, an alkyloxycarbonyl group, a honolemil group, or an alkyloxyl
- R 1 and R 2 may be cyclized by linking.
- R 3 is a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an aryl group, an amino group or a hydroxy group.
- R 4 and R 5 each independently represent a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, an alkyl group having 4 or more carbon atoms, or an aryl group.
- R 3 is hydrogen
- R 4 / R 5 is a hydrogen atom / methyl group or a methyl group / hydrogen atom
- the substitution position of OR 1 group / R 2 group is benzene.
- a compound at the 3- or 2-position on the ring and Excluding a compound in which one of R 4 or R 5 is a propyl group), a geometric isomer or an optically active isomer, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- R 1 is a hydrogen atom, a geometric isomer or an optically active form thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- R 6 represents an alkyl group, an aryl group, or an alkylamino group
- R 2 represents a formyl group
- a carboxy group, -CH _0 (C 0)
- R 7 represents an alkyl group, an aryl group, or an alkylamino group
- R 8 represents a hydrogen atom, an alkyl group, or an alkenyl group
- R 9 represents a hydrogen atom or an alkyl group
- -CH CH_R 1Q .
- R 9 represents a hydrogen atom or an alkyl group
- -CH CH_R 1Q .
- R 3 represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an aryl group, an amino group or a hydroxy group.
- R 4 and R 5 each independently represent a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, or a group having 4 or more carbon atoms.
- -R 6 represents an alkyl group, an aryl group, or an alkylamino group
- R 2 represents a formyl group
- a carboxy group, -CH _0 (C 0)
- R 7 represents an alkyl group, an aryl group, or an alkylamino group
- R 8 represents a hydrogen atom, an alkyl group, or an alkenyl group
- R 9 represents a hydrogen atom or an alkyl group
- -CH CH-R 1Q
- R 1Q represents an alkyl group, an alkyloxycarbonyl group, a honolemil group, or an alkyloxyl
- R 1 and R 2 may be cyclized by linking.
- R 3 is a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an aryl group, an amino group or a hydroxy group.
- R 4 and R 5 each independently represent a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, an alkyl group having 4 or more carbon atoms, or an aryl group.
- composition according to (8) which is a prophylactic or therapeutic agent for diabetes, obesity, nerve injury, or neurosis, or a protein tyrosine phosphorylation enhancer.
- -R 6 represents an alkyl group, an aryl group, or an alkylamino group
- R 7 represents an alkyl group, an aryl group, or an alkylamino group
- R 8 represents a hydrogen atom, an alkyl group, or an alkenyl group
- R 9 represents a hydrogen atom or an alkyl group
- -CH CH-R 1Q
- R 1Q represents an alkyl group, an alkyloxycarbonyl group, a honolemil group, or an alkyloxyl
- R 1 and R 2 may be cyclized by linking.
- R 3 is a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an aryl group, an amino group or a hydroxy group.
- R 4 and R 5 each independently represent a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, an alkyl group having 4 or more carbon atoms, or an aryl group)
- a prophylactic drug for diabetes or obesity which comprises one or more of any of the compounds represented by the following, geometric isomers or optically active forms thereof, pharmaceutically acceptable salts thereof, or hydrates thereof: Therapeutic drugs.
- a preventive or therapeutic agent for diabetes or obesity comprising one or more of any of the following: a body or an optically active form, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- _R 6 R 6 is an alkyl
- R 7 R 7 represents an alkyl group, an aryl group, or an alkylamino group.
- R 8 represents a hydrogen atom, an alkyl group, or an alkenyl group
- R 9 represents a hydrogen atom or an alkyl group
- -CH CH-R 1Q
- R 1Q represents an alkyl group, an alkyloxycarbonyl group, a honolemil group, or an alkyloxyl
- R 1 and R 2 may be cyclized by linking.
- R 3 is a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an aryl group, an amino group or a hydroxy group.
- R 4 and R 5 each independently represent a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, an alkyl group having 4 or more carbon atoms, or an aryl group)
- a preventive agent for nerve damage or neuropathy comprising one or more of the compounds represented by the following formulas, geometric isomers or optically active forms thereof, pharmaceutically acceptable salts thereof, or hydrates thereof: Or therapeutic drugs.
- R 1 is a hydrogen atom, a geometric isomer or an optically active form thereof, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- a preventive or therapeutic agent for nerve damage or neurosis including one or more of the following.
- a preventive or therapeutic agent for nerve damage or neuropathy comprising one or more of any of the following: a body or an optically active form, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- -R 6 represents an alkyl group, an aryl group, or an alkylamino group
- R 2 represents a formyl group
- a carboxy group, -CH _0 (C 0)
- R 7 represents an alkyl group, an aryl group, or an alkylamino group
- R 8 represents a hydrogen atom, an alkyl group, or an alkenyl group
- R 9 represents a hydrogen atom or an alkyl group
- -CH CH-R 1Q
- R 1Q represents an alkyl group, an alkyloxycarbonyl group, a honolemil group, or an alkyloxyl
- R 1 and R 2 may be cyclized by linking.
- R 3 is a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an aryl group, an amino group or a hydroxy group.
- R 5 independently represents a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, an alkyl group having 4 or more carbon atoms, or an aryl group), a geometric isomer or an optical isomer thereof
- An agent for enhancing protein tyrosine phosphorylation which comprises one or more of the active substance, a pharmaceutically acceptable salt thereof, or a hydrate thereof.
- R 1 , R 3 , R 6 , R 7 , R 8 , R 9 or R 1 May be independently any linear, branched or cyclic alkyl group, preferably an alkyl group having 110 carbon atoms, more preferably a methyl group, an ethyl group, or a propyl group.
- R 4 and R 5 are each independently a linear, branched or cyclic alkyl group, preferably a carbon atom.
- 110 alkyl groups more preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s_butyl, t-butyl, pentyl, s-pentyl, isopentyl , 2-methylbutyl, neopentyl, 1-ethylpropyl, hexyl, 4-methylopentyl (isohexyl), 3-methylpentyl, 2-methylpentyl, 1-methylopentyl (s-hexyl) ) Group, 3,3-dimethylbutyl group, 2,2-dimethylbutyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutynole Group
- R 1 or R 8 each independently represents a force that can be any linear, branched or cyclic alkenyl group. It is a 2-10 alkenyl group, more preferably a vinyl group, a propenyl group, an isopropyl group, a cyclopropenyl group, a butenyl group, a pentenyl group, a hexenyl group, a styryl group and the like.
- R 2 is a force S that can be a carboxyl group, the carboxyl group is a salt thereof, and a compound in which hydrogen of the carboxyl group is substituted with an arbitrary group. (Eg, esters).
- R 3 , R 4 , R 5 , R 6 or R 7 may be each independently any substituted or unsubstituted aryl group, but is preferably A substituted or unsubstituted phenyl group can be mentioned.
- R 6 or R 7 is each independently any alkylamino group
- R 1Q is any alkyloxycarbonyl group or any alkyloxycarbinolealkyl group
- R 3 may be an arbitrary alkoxy group (alkyloxy group).
- preferred groups of these groups include an alkyl moiety having 1 to 10 carbon atoms, more preferably methynole, ethyl and propyl.
- R 3 may be a halogen atom, such as a fluorine atom, a black atom, and a bromo atom.
- R 3 may be any amino group.
- the amino group also includes an arylamino group such as an anolequinolamino group, a dianolequinolamino group, and aniline.
- preferred compounds are those in which R 1 is hydrogen and / or Compounds in which 2 is a hydroxymethyl group are exemplified. Further, a compound in which the substitution position of the OR 1 group / R 2 group on the benzene ring is 2-position, 3-position, or 3-position, Z2-position, respectively, is also a preferred compound.
- More preferred conjugates are those wherein R 1 is hydrogen and / or R 2 is a hydroxymethyl group, and the substitution positional force of the OR 1 group / R 2 group on the benzene ring is 2 / A compound at the 3-position or 3-position / 2 position, more preferably R 1 is hydrogen and / or R 2 is a hydroxymethyl group, and OR 1 group / R 2 group on the benzene ring Is a compound having a 3-position / 2-position.
- the most preferred compounds according to the present invention include the following compounds, but the present invention is not limited to these compounds.
- each of the following compounds may be referred to by using the code number shown in the parentheses in this specification.
- R 6 represents an alkyl group, an aryl group, or an alkylamino group
- R 2 represents a formyl group
- a carboxy group, -CH _0 (C 0)
- R 7 represents an alkyl group, an aryl group, or an alkylamino group
- R 8 represents a hydrogen atom, an alkyl group, or an alkenyl group
- R 9 represents a hydrogen atom or an alkyl group
- -CH CH-R 1Q
- R 1Q represents an alkyl group, an alkyloxycarbonyl group, a honolemil group, or an alkyloxyl
- R 1 and R 2 may be cyclized by linking.
- R 3 is a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an aryl group, an amino group or a hydroxy group.
- R 4 and R 5 each independently represent a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, an alkyl group having 4 or more carbon atoms, or an aryl group, and L represents a sulfonate group or a halogen atom.
- X represents B (OR u ) (R 11 represents hydrogen or an alkyl group) or Sn (R 12 ) (R 12 represents an alkyl group).
- L may be any substituent or atom as long as the compound represented by ( ⁇ ) is a substituent or an atom capable of undergoing an oxidative addition reaction to the catalyst in Scheme 1.
- R 11 in X is hydrogen or any alkyl group including an isopropyl group.
- Sell force is preferably hydrogen, also R 12 is force-methyl group can be any alkyl group, a butyl group and the like.
- reaction shown in Scheme 1 is performed by reacting a compound represented by the general formula (III) and a compound represented by the general formula (IV) in an inert solvent in the presence of a base and in the presence of a transition metal catalyst.
- a compound represented by the general formula (III) and a compound represented by the general formula (IV) in an inert solvent in the presence of a base and in the presence of a transition metal catalyst.
- a base and in the presence of a transition metal catalyst.
- a transition metal catalyst can be.
- another compound for example, a phosphine ligand
- the inert solvent used in the reaction shown in Scheme 1 is not particularly limited as long as it is inert to the reaction, and examples thereof include aliphatic hydrocarbons such as hexane, benzene, and toluene. And aryl hydrocarbons, chloroform, halogenated hydrocarbons such as dichloromethane, and ethers such as getyl ether and tetrahydrofuran.
- the base used in the reaction shown in Scheme 1 is not particularly limited as long as it does not affect the other parts of the compound, and may be an organic base or an inorganic base. Force Preferably, potassium carbonate etc. are mentioned, for example.
- a transition metal complex such as a palladium catalyst or a nickel catalyst can be mentioned, preferably a palladium catalyst, and particularly preferably tetrakis (triphenylphosphine) palladium Is mentioned.
- the reaction temperature of the reaction shown in Scheme 1 is a force that can be appropriately selected depending on the starting compound, the solvent, and the like, and is usually 40 to 80 ° C.
- the reaction time varies depending on the starting compound, solvent, reaction temperature and the like, but is usually 2 to 12 hours.
- the compound represented by the general formula (III) may be protected (for example, cyclized) with a protecting group, if necessary.
- Examples of the protected compound include a compound represented by the following general formula (m) _i.
- the compound represented by the general formula ( ⁇ ) can be produced, for example, by subjecting a compound represented by the general formula (I) to a hydrogenation reaction as shown in the following scheme. it can.
- a person skilled in the art can select an appropriate hydrogenation reaction in this reaction, but a hydrogenation reaction using a heterogeneous catalyst containing palladium-carbon, or a hydrogenation reaction using a homogeneous catalyst containing a Wilkinson complex is preferable. Is also good.
- a preferable hydrogenation reaction can be carried out, for example, by performing the reaction in methanol using a palladium-carbon catalyst under a hydrogen atmosphere.
- the compound represented by the general formula (I) or ( ⁇ ) is analyzed by melting point, infrared absorption spectrum, 1 H_NMR spectrum, 13 C_NMR spectrum, mass spectrometry, X-ray structure analysis, etc., as necessary. , Confirmation and identification.
- salts include alkali metal salts such as sodium salt, potassium salt and lithium salt, alkaline earth metal salts such as calcium salt and magnesium salt, aluminum salt, iron salt, zinc salt, and copper salt.
- Metal salts such as salts, nickel salts, cobalt salts and the like can be mentioned.
- the compound according to the present invention may have one or more asymmetric carbon atoms depending on the type of the substituent.
- stereoisomers such as optical isomers or diastereomers based on these asymmetric carbons exist, the scope of the present invention includes pure stereoisomers as well as mixtures or racemates of any stereoisomers. Is included.
- the compound according to the present invention may have an olefinic double bond, and may have a geometrical isomer based on a double bond. Mixtures of isomers are also within the scope of the present invention.
- the compound according to the present invention can exist in any crystalline form, and may exist as a hydrate or a solvate. It goes without saying that all of these substances are included in the scope of the present invention. Further, the present invention relates to the present invention Compounds that are converted to trisubstituted benzene derivative compounds, ie, all so-called prodrugs are also included.
- the compounds according to the present invention exhibit excellent insulin action enhancing action and Z or neurotrophic factor enhancing action as described in Test Examples described later.
- composition according to the present invention can be used as a therapeutic or therapeutic agent for various diseases such as diabetes and obesity, and diseases such as nerve damage and neurosis. It can be used as a prophylactic, and can be administered to humans, for example.
- the composition containing the compound according to the present invention can be used as a protein tyrosine phosphorylation enhancer, and can be administered to a human, for example.
- the protein tyrosine phosphorylation enhancer can be used, for example, as a therapeutic or preventive agent for diseases such as diabetes and obesity, and nerve damage and neurosis. That is, the therapeutic or prophylactic agent for diseases such as diabetes and obesity and nerve damage and neuropathy of the present invention may be an embodiment of a protein tyrosin phosphorylation enhancer.
- Examples of the dosage form of the reagent containing the compound according to the present invention include a solid agent such as a powder, and a liquid agent dissolved in an organic solvent or a water-containing organic solvent.
- examples of the organic solvent that can be used include methanol and dimethyl sulfoxide.
- the effective dose is 0.1 to 100 ⁇ g / ml. The appropriate dose depends on the type and purpose of the cultured cell line and can be appropriately selected. . If necessary, an amount outside the above range may be used.
- composition according to the present invention is mixed with excipients, binders, wetting agents, disintegrants, lubricants and other pharmaceutical additives as appropriate for the dosage form. May be. That is, except for containing the compound according to the present invention, a pharmaceutical preparation can be prepared by a usual method. Book Examples of the dosage form of the composition according to the present invention include powders, granules, tablets, capsules, pills, solutions, injections, suppositories, transdermal absorbents, inhalants and the like. When preparing an injection, it can be formulated by sterilizing with an appropriate carrier.
- composition according to the present invention is orally administered in the case of powders, granules, tablets, capsules, pills, liquids, and the like, or injections, suppositories, transdermal absorbents, inhalants. In such cases, it can be administered parenterally.
- the dose of the compound according to the present invention also varies depending on the disease state, administration route, patient's age, or body weight, and is ultimately left to the judgment of a physician.
- Mouse preadipocytes 3T3-L1 were cultured and maintained in a DMEM medium containing 10% fetal calf serum (FBS). 3T3-L1 cells were seeded on a 12-well plastic plate at 5xl0 5 cells / ml, cultured for 3 days (37 ° C, 5% CO 2), and synchronized with the GO phase by contact inhibition. Next, the medium
- the medium was replaced with a 10% FBS_DMEM medium, and 500 ⁇ M 3_isobutyl_1_methylxanthine ( ⁇ ), 1 ⁇ dexamethasone, and 1 ⁇ g / ml insulin were added. This was cultured for 2 days as a differentiation induction medium. Then remove the medium and wash with phosphate buffer. After purification, the cells were differentiated into mature adipocytes cultured for 5 days.
- RKTS-101 or RKTS-102 in a series of dilution series (0.31030 ⁇ m) was added to mature adipocytes, and after 1 hour of culture, ⁇ insulin was added. After 4 hours, each cell is solubilized and subjected to SDS (sodium lauryl sulfate) -polyacrylamide electrophoresis, and then the degree of intracellular cleaved phosphorylation is detected by Western blotting using anti-phosphotyrosine antibody (UPSTATE) did.
- SDS sodium lauryl sulfate
- UPSTATE anti-phosphotyrosine antibody
- RKTS-101 and RKTS-102 markedly induced insulin-induced enhancement of intracellular tyrosine phosphorylation in mature 3T3-L1 cells in the concentration range of 3-100 ⁇ g / ml, respectively.
- Table 1 This indicates that the compound of the present invention has an insulin action-enhancing activity and is useful as a preventive or therapeutic drug for diabetes and obesity.
- the degree of intracellular tyrosine phosphorylation is classified into three stages.
- the degree of intracellular tyrosine phosphorylation by stimulation with insulin alone (+) is 2
- An increase of about two-fold (++) and an increase of more than two-fold relative to the degree of intracellular tyrosine phosphorylation by stimulation with insulin alone (+++) are shown.
- Rat pheochromocytoma cells were maintained in DMEM medium containing 5% fetal calf serum (FBS) and 5% bovine serum (CS). 24 ⁇ El plastic plate so as to 3xl0 4 cells / 500 ⁇ 1 seeded PC12 cells were over ⁇ cultured (37 ° C 5% CO) . Then a series of dilution series RKTS-101,
- a novel trisubstituted benzene derivative can be provided.
- the preferred conjugate according to the present invention has an effect of enhancing the protein tyrosine phosphorylation level at the cultured cell level.
- preferred compositions comprising the compounds according to the invention Is useful as a preventive and therapeutic drug for neuropathy including diabetes, obesity, nerve damage, Alzheimer's disease, Parkinson's disease and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005506199A JP4624260B2 (ja) | 2003-05-14 | 2004-05-14 | 新規3置換ベンゼン誘導体、その製造方法、およびそれを含む医薬組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003136445 | 2003-05-14 | ||
JP2003-136445 | 2003-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004101483A1 true WO2004101483A1 (ja) | 2004-11-25 |
Family
ID=33447227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/006546 WO2004101483A1 (ja) | 2003-05-14 | 2004-05-14 | 新規3置換ベンゼン誘導体、その製造方法、およびそれを含む医薬組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4624260B2 (ja) |
WO (1) | WO2004101483A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6434913A (en) * | 1987-07-31 | 1989-02-06 | Mitsubishi Chem Ind | Antitumor agent |
WO2002096866A2 (en) * | 2001-05-30 | 2002-12-05 | Guilford Pharmaceuticals Inc. | Thiolalkyl benzoic acid derivatives |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8400239D0 (sv) * | 1984-01-19 | 1984-01-19 | Pharmacia Ab | Nya arylettiksyraderivat |
JPS63115834A (ja) * | 1986-10-31 | 1988-05-20 | Green Cross Corp:The | 芳香族化合物 |
JPH02170165A (ja) * | 1988-12-23 | 1990-06-29 | Hitachi Ltd | 放射線感応性組成物及びそれを用いたパターン形成法 |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
FR2785284B1 (fr) * | 1998-11-02 | 2000-12-01 | Galderma Res & Dev | Analogues de la vitamine d |
AU6661901A (en) * | 2000-05-30 | 2001-12-11 | Guilford Pharm Inc | Naaladase inhibitors for treating retinal disorders and glaucoma |
-
2004
- 2004-05-14 JP JP2005506199A patent/JP4624260B2/ja not_active Expired - Fee Related
- 2004-05-14 WO PCT/JP2004/006546 patent/WO2004101483A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6434913A (en) * | 1987-07-31 | 1989-02-06 | Mitsubishi Chem Ind | Antitumor agent |
WO2002096866A2 (en) * | 2001-05-30 | 2002-12-05 | Guilford Pharmaceuticals Inc. | Thiolalkyl benzoic acid derivatives |
Non-Patent Citations (1)
Title |
---|
FÜRSTNER A. ET AL: "Shortcut syntheses of naturally occurring 5-alkylresorcinols with DNA-cleaving properties", J. ORG. CHEM., vol. 62, no. 8, 1997, pages 2332 - 2336, XP002980998 * |
Also Published As
Publication number | Publication date |
---|---|
JP4624260B2 (ja) | 2011-02-02 |
JPWO2004101483A1 (ja) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6926189B2 (ja) | エストロゲン受容体調節薬 | |
CN111484477A (zh) | 一种苯并吡啶酮杂环化合物及其用途 | |
CN113501821B (zh) | 具有mgat-2抑制活性的稠合环衍生物 | |
EA018413B1 (ru) | Фармацевтические композиции на основе катехоламиновых производных и их применение | |
KR20080004632A (ko) | 신규 락탐 화합물 | |
CN105263924B (zh) | Cxcr7受体调节剂 | |
SA95160203B1 (ar) | مشتقات بيرولوكربازول كيميائية علاجية Chemotheraqeutic Pyrrolocarbazole Derivatives | |
TW201035097A (en) | 9H-pyrrolo[2,3-b:5,4-c']dipyridine azacarboline derivatives, preparation and therapeutic use thereof | |
WO1995005374A1 (fr) | Derive de cyclopentene heteroaromatique fusionne ayant une activite antagoniste de l'endotheline | |
EA015745B1 (ru) | Соединения, проявляющие активность в отношении св | |
RU2569061C2 (ru) | Ингибиторы амид-гидролазы жирных кислот | |
JP7106659B2 (ja) | インドール-2、3-ジオキシゲナーゼ阻害剤としてのスピロ化合物 | |
IE61006B1 (en) | New tricyclic amines derived from 2,3,5,6,7,8-hexahydronaphto (2,3-b) furan and from 2,3,6,7,8,9-hexahydro-5H-benzocyclohepta (2,3-b) furan, the processes for preparing them and the pharmaceutical compositions which contain them | |
KR20170033684A (ko) | 리나글립틴 결정형 및 이의 제조방법 | |
EP3395798A1 (en) | Non-aromatic heterocyclic derivative having mgat2 inhibitory activity | |
CN113272315A (zh) | 一类类固醇化合物及其用途 | |
WO2004101483A1 (ja) | 新規3置換ベンゼン誘導体、その製造方法、およびそれを含む医薬組成物 | |
CA3197220A1 (en) | 2-pyridones as thyroid hormone receptor modulators | |
JP7278273B2 (ja) | アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン | |
WO2021226020A1 (en) | Polymorphic forms of (r)-oxybutynin hydrochloride | |
EP3909583A1 (en) | Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity | |
EP0220409B1 (en) | Gem-dihalo and tetrahalo-1,12-diamino-4,9-diaza-dodecanes | |
WO2000044721A1 (fr) | Derives indole 3, 7-de-substitues et compositions medicales les renfermant | |
JPH08134067A (ja) | キヌクリジン誘導体 | |
KR20140064987A (ko) | 콜린 키나제의 억제제로서 유용한 화합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005506199 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |